Skin Cancer Screenings: Why Are the Benefits in Question?

Main Article Content

Nicholas Brownstone
Darrell Rigel


melanoma, screening, skin cancer, overdiagnosis


Abstract not available. 


1. Matsumoto M, Wack S, Weinstock MA, et al. Five-Year Outcomes of a Melanoma Screening Initiative in a Large Health Care System. JAMA Dermatol. Published online April 06, 2022. doi:10.1001/jamadermatol.2022.0253

2. Swerlick RA. Melanoma Screening—Intuition and Hope Are Not Enough. JAMA Dermatol. Published online April 6, 2022. doi:10.1001/jamadermatol.2022.0082

3. Kulkarni RP, Yu WY, Leachman SA. To Improve Melanoma Outcomes, Focus on Risk Stratification, Not Overdiagnosis. JAMA Dermatol. Published online April 6, 2022. doi:10.1001/jamadermatol.2022.0097

4. Rigel DS, Friedman RJ, Kopf AW, et al. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol 1986;14:857-60.

5. Geller AG, Zi Z, Sober A, et al. The first 15 years of the American Academy of Dermatology Skin Cancer Screening Programs: 1985-1999. (J Am Acad Dermatol 2003;48:34-41.

6. Siegel R, Miller K, Fuchs H, et al. Cancer statistics, 2022. CA CANCER J CLIN 2022;72:7–33

7. Waqas R. Shaikh, Stephen W. Dusza, Martin A. Weinstock, Susan A. Oliveria, Alan C. Geller, Allan C. Halpern, Melanoma Thickness and Survival Trends in the United States, 1989–2009, JNCI: Journal of the National Cancer Institute, Volume 108, Issue 1, January 2016, djv294,

Most read articles by the same author(s)

1 2 > >>